Nurse's Pocket Drug Guide 2009

Total Page:16

File Type:pdf, Size:1020Kb

Nurse's Pocket Drug Guide 2009 NURSE’S POCKET DRUG GUIDE 2009 EDITOR Judith A. Barberio, PhD, APN,C, ANP, FNP, GNP CONSULTING EDITOR Leonard G. Gomella, MD, FACS ASSOCIATE EDITORS Steven A. Haist, MD, MS, FACP Aimee Gelhot Adams, PharmD Kelly M. Smith, PharmD, FASHP New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2009 by Judith A. Barberio. All rights reserved. Manufactured in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher. 0-07-164280-3 The material in this eBook also appears in the print version of this title: 0-07-154970-6. All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps. McGraw-Hill eBooks are available at special quantity discounts to use as premiums and sales pro- motions, or for use in corporate training programs. For more information, please contact George Hoare, Special Sales, at [email protected] or (212) 904-4069. TERMS OF USE This is a copyrighted work and The McGraw-Hill Companies, Inc. (“McGraw-Hill”) and its licen- sors reserve all rights in and to the work. Use of this work is subject to these terms. Except as per- mitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill’s prior consent. You may use the work for your own noncommer- cial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms. THE WORK IS PROVIDED “AS IS.” McGRAW-HILL AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COM- PLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUD- ING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regard- less of cause, in the work or for any damages resulting therefrom. McGraw-Hill has no responsi- bility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill and/or its licensors be liable for any indirect, incidental, special, punitive, conse- quential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise. DOI: 10.1036/0071549706 Professional Want to learn more? We hope you enjoy this McGraw-Hill eBook! If you’d like more information about this book, its author, or related books and websites, please click here. For more information about this title, click here CONTENTS EDITORS v PREFACE vii MEDICATION KEY ix ABBREVIATIONS xiii CLASSIFICATION 1 Allergy 1 Antidotes 1 Antimicrobial Agents 1 Antifungals 3 Antineoplastic Agents 4 Antiretrovirals 6 Cardiovascular (CV) Agents 6 Central Nervous System Agents 9 Dermatologic Agents 10 Dietary Supplements 11 Ear (OTIC) Agents 12 Endocrine System Agents 12 Eye (Ophthalmic) Agents 13 Gastrointestinal Agents 15 Hematologic Agents 16 Immune System Agents 17 Musculoskeletal Agents 19 OB/GYN Agents 19 Pain Medications 21 Respiratory Agents 22 Urinary/Genitourinary Agents 23 Wound Care 24 Miscellaneous Therapeutic Agents 24 Natural & Herbal Agents 24 iii iv Contents GENERIC AND SELECTED BRAND DRUG DATA 25 COMMONLY USED MEDICINAL HERBS 296 TABLES 309 INDEX 335 EDITORS EDITOR Judith A. Barberio, PhD, APN,C, ANP, FNP, GNP Assistant Professor Coordinator, Adult & Family Nurse Practitioner Tracks Rutgers, The State University of New Jersey College of Nursing Newark, New Jersey CONSULTING EDITOR Leonard G. Gomella, MD, FACS The Bernard W. Godwin, Jr., Professor Chairman, Department of Urology Jefferson Medical College Associate Director of Clinical Affairs Kimmel Cancer Center Thomas Jefferson University Philadelphia, Pennsylvania ASSOCIATE EDITORS Steven A. Haist, MD, MS, FACP Professor of Medicine Associate Chair for Education and Residency Program Director Department of Internal Medicine University of Kentucky Medical Center Lexington, Kentucky Aimee Gelhot Adams, PharmD Assistant Professor College of Pharmacy and Department of Internal Medicine Clinical Specialist, Primary Care University of Kentucky Medical Center Lexington, Kentucky v Copyright © 2009 by Judith A. Barberio. Click here for terms of use. vi Editors Kelly M. Smith, PharmD, FASHP Associate Professor Department of Pharmacy Practice and Science University of Kentucky College of Pharmacy Clinical Specialist, Medical Use Policy University of Kentucky Medical Center Lexington, Kentucky PREFACE WE ARE PLEASED TO PRESENT THE FIFTH EDITION OF THE NURSE’S POCKET DRUG GUIDE. Our goal is to identify the most frequently used and clinically important medications, including branded, generic, and OTC prod- ucts. The book includes over 1000 generic medications and is designed to repre- sent a cross section of commonly used products in health care practices across the country. The style of drug presentation includes key “must know” facts of commonly used medications and herbs, essential information for the student, practicing nurse, and health care provider. The inclusion of common uses of medications rather than just the official FDA-labeled indications are based on the uses of the medication and herbs supported by publications and community standards of care. All uses have been reviewed by our editorial board. It is essential that students, registered nurses, and advanced-practice nurses learn more than the name and dose of the medications they administer and pre- scribe. Certain common side effects and significant contraindications are associ- ated with most prescription medications. Although nurses and other health care practitioners should ideally be completely familiar with the entire package insert of any medication prescribed, such a requirement is unreasonable. References such as the Physicians’ Desk Reference and the drug manufacturer’s Web site make pack- age inserts readily available for many medications, but may not highlight clinically significant facts or key data for generic drugs and those available over the counter. The limitations of difficult-to-read package inserts were acknowledged by the Food and Drug Administration in early 2001, when it noted that health care providers do not have time to read the many pages of small print in the typical package insert. Newer drugs are producing more user-friendly package insert sum- maries that will highlight important drug information for easier nursing reference. Although useful, these summaries do not commingle with similarly approved generic or “competing” similar products. The editorial board has analyzed the information on both brand and generic medications and has made this key prescribing information available in this pocket-sized book. Information in this book is meant for use by health care profes- sionals who are familiar with these commonly prescribed medications. This 2009 edition has been completely reviewed and updated by our editorial board. Over 55 new drugs and herbs have been added, and changes in other vii Copyright © 2009 by Judith A. Barberio. Click here for terms of use. viii Preface medications based on FDA actions have been incorporated, including deletions of discontinued brand names and compounds. New to this edition are the therapeutic and pharmacologic classifications for each drug and a section on commonly used vitamin combinations. Where appropriate, emergency cardiac care (ECC) guidelines are provided based on the latest recommendations for the American Heart Association (Circula- tion, Volume 112, Issue 24 Supplement; December 13, 2005). We express special thanks to our families for their long-term support of this book. The contributions of the members of the editorial board are deeply appreci- ated. The assistance of Quincy McDonald, and the team at McGraw-Hill are also to be thanked for their support in our goal of creating a pocket drug guide for nursing professionals. Your comments and suggestions are always welcome and encouraged because improvements to this book would be impossible without the interest and feedback of our readers. We hope this book will help you learn some of the key elements in prescribing medications and allow you to care for your patients in the best way possible. Judith A. Barberio, PhD, APN,C, ANP, FNP, GNP Newark, New Jersey [email protected] Leonard G. Gomella, MD, FACS Philadelphia, Pennsylvania [email protected] MEDICATION KEY Medications are listed by prescribing class, and the individual medications are then listed in alphabetical order by generic name. Some of the more commonly recog- nized trade names are listed for each medication (in parentheses after the generic name) or if available without prescription, noted as OTC (over the counter). Generic Drug Name (Selected Common Brand Names [Controlled Substance]) WARNING: Summarized version of the “Black Box” precautions deemed necessary by the FDA.
Recommended publications
  • Caring for the Infant with Neonatal Abstinence Syndrome (NAS)
    Dandle•LION products provide supportive care for infants with NAS Caring for the Infant with Neonatal Abstinence Syndrome (NAS) According to the American Academy of Pediatrics (2012), nonpharmacologic care strategies should comprise the initial approach to therapy in treating Neonatal Abstinence Syndrome. NAS is a self-limiting condition where the primary goal of the care team is to decrease symptoms without extraneous pharmacological and medical intervention. Successful management of neonatal withdrawal symptoms rests on a foundation of supportive care for mother and infant, with active participation from a multi-disciplinary care team. Evidence- based strategies include providing a calm environment with decreased visual and auditory stimuli, promoting sleep for parents and infant, providing positive proprioceptive and tactile sensory input, and maximizing nutrition to promote weight gain. Ideally, infant and family remain together for the duration of the hospital stay in a quiet, protected environment with Therapeutic Positioning Skin Protection Therapeutic Touch Protective Environment medical and psychosocial support that continues beyond hospitalization. The DandleWRAP Stretch is Preventing diaper dermatitis is Infant massage provides babies Swaddled, immersion bathing designed to support irritable, hard- essential to promoting comfort in with a positive tactile experience promotes temperature stability to-console babies. The lightweight, babies with NAS. Frequent stooling that promotes proprioception and creates a relaxing and calm American Academy of Pediatrics (2017). Alternative treatment approach for neonatal Holmes, A., Atwood, E. Whalen, B. Beliveau, J., Jarvis, J., Matulis, J. & Ralston, S. (2016). abstinence syndrome may shorten hospital stay. AAP News. Accessed online September Rooming-in to treat neonatal abstinence syndrome: Improved family-centered care at lower moisture-wicking fabric reduces can change the pH of the baby’s and encourages development experience for irritable babies.
    [Show full text]
  • Neonatal Abstinence Syndrome Guideline
    Neonatal Abstinence Syndrome MENU Introduction Incidence and risk factors 1. Risk factors for illicit drug use 2. Risk factors for adverse pregnancy outcomes 3. Risk factors for neonatal abstinence syndrome Consequences 1. Tobacco 2. Alcohol 3. Amphetamines 4. Cocaine and derivatives 5. Marijuana 6. Opiates 7. Polydrug use Diagnosis 1. Drug use in pregnancy 2. Testing of newborns 3. Diagnosis of withdrawal Interventions 1. Antenatal care a. Treatment of pregnant users of illicit drugs b. Smoking in pregnancy c. Support from caregivers for pregnant women abusing drugs 2. Postnatal care 3. Pharmacological treatment a. Opioid withdrawal: MORPHINE REGIMEN b. Non-opioid CNS depressants: PHENOBARBITONE REGIMEN c. Management of the vomiting baby Discharge The Drug use in pregnancy team Infant protection issues Follow-Up Keypoints References Introduction: Pregnant women using drugs have the same anxieties and expectations as other pregnant women. All women using drugs are entitled to accurate information, and to be treated sensitively in a non-judgmental manner. Maternal illicit drug use is a risk factor for adverse pregnancy and neonatal outcomes including preterm birth. Infants born to mothers using illicit drugs (and alcohol and tobacco) are at risk of the toxic effects of the drugs both in-utero and ex-utero; adverse pregnancy and neonatal outcomes related to the poor socioeconomic situations and lifestyle factors associated with illicit drug use; neonatal drug withdrawal; and the subsequent poor outcomes of infants reared in a socioeconomically disadvantaged environment. The Report of the US Preventative Services Task Force 1996 1 and the monograph review by Bell and Lau 2 1995 are used as background for the content of this guideline.
    [Show full text]
  • Neonatal Drug Withdrawal Abstract
    Guidance for the Clinician in Rendering Pediatric Care CLINICAL REPORT Neonatal Drug Withdrawal Mark L. Hudak, MD, Rosemarie C. Tan, MD,, PhD, THE abstract COMMITTEE ON DRUGS, and THE COMMITTEE ON FETUS AND Maternal use of certain drugs during pregnancy can result in transient NEWBORN neonatal signs consistent with withdrawal or acute toxicity or cause KEY WORDS opioid, methadone, heroin, fentanyl, benzodiazepine, cocaine, sustained signs consistent with a lasting drug effect. In addition, hos- methamphetamine, SSRI, drug withdrawal, neonate, abstinence pitalized infants who are treated with opioids or benzodiazepines to syndrome provide analgesia or sedation may be at risk for manifesting signs ABBREVIATIONS of withdrawal. This statement updates information about the clinical CNS—central nervous system — presentation of infants exposed to intrauterine drugs and the thera- DTO diluted tincture of opium ECMO—extracorporeal membrane oxygenation peutic options for treatment of withdrawal and is expanded to include FDA—Food and Drug Administration evidence-based approaches to the management of the hospitalized in- 5-HIAA—5-hydroxyindoleacetic acid fant who requires weaning from analgesics or sedatives. Pediatrics ICD-9—International Classification of Diseases, Ninth Revision — – NAS neonatal abstinence syndrome 2012;129:e540 e560 SSRI—selective serotonin reuptake inhibitor INTRODUCTION This document is copyrighted and is property of the American fi Academy of Pediatrics and its Board of Directors. All authors Use and abuse of drugs, alcohol, and tobacco contribute signi cantly have filed conflict of interest statements with the American to the health burden of society. The 2009 National Survey on Drug Use Academy of Pediatrics. Any conflicts have been resolved through and Health reported that recent (within the past month) use of illicit a process approved by the Board of Directors.
    [Show full text]
  • Download This PDF File
    Chimica Analitica ANA-KN-01 Functionalized carbon nanostructures and metal nanoparticles: from effective charge propagation to enhancement of electrocatalytic, photoelectrocatalytic and bioelectrocatalytic properties Pawel J. Kulesza Department of Chemistry, University of Warsaw, Pasteura 1, PL-02-093 Warsaw, Poland * [email protected] Of particular interest to the preparation of advanced materials is synthesis and characterization of carbon nanostructures (e.g. nanotubes) and noble metal nanoparticles, their stabilization (e.g. through self-assembly), as well as organization into two-dimensional arrays and controlled fabrication (e.g. through the sequential attraction) into three-dimensional network films. They can form nanosized materials with well-defined composition, structure and thickness. The interfaces can be also highly functionalized, and they can exhibit specific catalytic or unique electronic, charge storage, optical and sensing properties. We explore here the ability of inorganic structures to stabilize and derivatize metal and carbon nanostructures. Among inorganic systems, polyoxometallates of molybdenum and tungsten are attractive since they can not only adsorb irreversibly on solid surfaces but also exhibit reversible stepwise multielectron transfer reactions. The concept of the layer-by-layer formation of hybrid (organic-inorganic) assemblies composed of anionic polyoxometallate-protected carbon nanotubes (or metal nanoparticles) and ultra-thin films of positively charged conducting polymers (e.g. such as polyaniline or PEDOT) will be described and discussed here. The resulting novel composite materials have been fabricated as thin or moderately thick (µm level) films on electrode surfaces. As evidenced from STM and scanning electron microscopy, their morphology is still granular but the structure is fairly dense. Further, they are characterized by fast dynamics of charge propagation.
    [Show full text]
  • Finnegan Neonatal Abstinence Scoring System: Normal Values for First 3 Days and Weeks 5–6 in Non-Addicted Infantsadd 2802 524
    RESEARCH REPORT doi:10.1111/j.1360-0443.2009.02802.x Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5–6 in non-addicted infantsadd_2802 524..528 Urs Zimmermann-Baer1,2, Ursula Nötzli1, Katharina Rentsch3 & Hans Ulrich Bucher1 Division of Neonatology, Department of Obstetrics and Gynecology, University Hospital Zurich, Switzerland,1 Division of Neonatology, Department of Pediatrics, Children’s Hospital, Kantonsspital Winterthur, Switzerland2 and Institute for Clinical Chemistry, University Hospital Zurich, Switzerland3 ABSTRACT Objective The neonatal abstinence scoring system proposed by Finnegan is used widely in neonatal units to initiate and to guide therapy in babies of opiate-dependent mothers. The purpose of this study was to assess the variability of the scores in newborns and infants not exposed to opiates during the first 3 days of life and during 3 consecutive days in weeks 5 or 6. Patients and methods Healthy neonates born after 34 completed weeks of gestation, whose parents denied opiate consumption and gave informed consent, were included in this observational study.Infants with signs or symptoms of disease or with feeding problems were excluded. A modified scoring system was used every 8 hours during 72 hours by trained nurses; 102 neonates were observed for the first 3 days of life and 26 neonates in weeks 5–6. A meconium sample and a urine sample at weeks 5–6 were stored from all infants to be analysed for drugs when the baby scored high. Given a non-Gaussian distribution the scores were represented as percentiles. Results During the first 3 days of life median scores remained stable at 2 but the variability increased, with the 95th percentile rising from 5.5 on day 1 to 7 on day 2.
    [Show full text]
  • Simplification of the Finnegan Neonatal Abstinence Scoring System: Retrospective Study of Two Institutions in the USA
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-016176 on 27 September 2017. Downloaded from Simplification of the Finnegan Neonatal Abstinence Scoring System: retrospective study of two institutions in the USA Enrique Gomez Pomar,1 Loretta P Finnegan,2 Lori Devlin,3 Henrietta Bada,1 Vanessa A Concina,1 Katrina T Ibonia,1 Philip M Westgate4 To cite: Gomez Pomar E, ABSTRACT Strengths and limitations of this study Finnegan LP, Devlin L, et al. Objective To develop a simplified Finnegan Neonatal Simplification of the Finnegan Abstinence Scoring System (sFNAS) that will highly ► A simplified scoring system (simplified Finnegan Neonatal Abstinence Scoring correlate with scores ≥8 and ≥12 in infants being System: retrospective Neonatal Abstinence Scoring System (sFNAS)) is assessed with the FNAS. study of two institutions proposed developed from a large data set and cross- Design, setting and participants This is a in the USA. BMJ Open validated using a database from another institution. retrospective analysis involving 367 patients admitted to 2017;7:e016176. doi:10.1136/ ► Cutoff values are provided for the sFNAS which two level IV neonatal intensive care units with a total of bmjopen-2017-016176 predict the cutoff value. 40 294 observations. Inclusion criteria included neonates ► The retrospective nature of our study requires ► Prepublication history for with gestational age ≥37 0/7 weeks, who are being this paper is available online. prospective validation of the inter-rater reliability of assessed for neonatal abstinence syndrome (NAS) using To view these files, please visit the sFNAS and also the clinical validity of this tool.
    [Show full text]
  • Testing Kits for Kinesiologists & Natural Therapists
    Testing Kits for Kinesiologists & Natural Therapists The kits come in easy seal bags and boxes are available separately for storage if required (see below). Postage will range from $7.00 to $13.00 ($12 to $26 for Express). The prices of these kits may change from time to time. Please check before or when ordering as to any prices changes. Individual vials may be purchased from kits for $17 each (or $13 each for 7 or more). Other single vials & update vials - see pages back of manual This manual is available at $29.00 plus $7.00 postage. With kit purchases it is available at a basic price of $19.00. After an initial purchase, any updated or later editions can be purchased at $15.00 plus $7.00 postage. Testing Kit Boxes & Empty Vials: Test Kit Box for 50 Vials (plastic box - vials upright): $13.00 or $10.00 with kits Test Kit Box for 100 Vials (plastic box - vials upright): $17.00 or $14.00 with Kits Test Kit Box for 72 vials (flat cardboard box with foam inlay – vials lay flat): $42 or $35 with kits Empty Vials for Liquids: 8 x 40 mm glass vial with plastic top: $6.00 per 10 vials or $52.00 per 100 pack. Empty Vials for Solids: 10 x 40mm glass vial with plastic top: $8.00 per 10 vials or $69.00 per 100 pack Pathology & Histology Testing Kits A Range of Kinesiological Testing Kits for Anatomy & Pathologies of the Body Organs & Systems (contents lists included in this manual) see contents page 3 Flower Essences We supply a variety of Flower Essences, and other types of Essences, plus accessories.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • Compatibility Mode
    11/16/2010 DIURETIK Diuretik & Anti-Diuretik VOLUME URINE Dept. Farmakologi dan Terapeutik, Fakultas Kedokteran Universitas Sumatera Utara ANTI DIURETIK PENGHAMBAT Classes of Diuretics: DIURETIK KARBONIK OSMOTIK Definitions ANHIDRASE Diuretic: • substance that promotes the DIURETIKDIURETIK excretion of urine DIURETIK DIURETIK HEMAT Natriuretic: KUAT KALIUM • substance that promotes the renal excretion of sodium TIAZID 1 11/16/2010 Diuretik osmotik Osmotic Diuretic Osmotic Diuretic Mechanism of Action: Characteristics Inhibition of Water Diffusion • Oral absorption: ( - ), parenteral • Free filtration in osmotically active administration concentration • Freely filterable • Osmotic pressure of non-reabsorbable solute prevents water reabsorption and • Little or no tubular reabsorption increase urine volume • Inert or non-reactive – Proximal tubule • Resistant to degradation by tubules – Thin limb of the loop of Henle 2 11/16/2010 Therapeutic Uses Osmotic Diuretics in Current Use Prophylaxis of renal failure • Mannitol (prototype) Mechanism: • Urea • Drastic reductions in GFR cause dramatically increased proximal tubular • Glycerin water reabsorption and a large drop in urinary excretion • Isosorbide • Osmotic diuretics are still filtered under these conditions and retain an equivalent amount of water, maintaining urine flow Therapeutic Uses (Cont.) Toxicity of Osmotic Diuretics • Increased extracellular fluid volume Reduction of pressure in extravascular fluid compartments • Hypersensitivity reactions • Glycerin metabolism can lead to •
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • The Carnivore Code Paul Saladino, M.D
    By dag Forssell, Jan 23, 2021 Comments: [email protected] Salicylates as discussed in The Carnivore Code Paul Saladino, M.d. CHAPTER 5: OF UNICORNS AND FAIRY TALES PERHAPSCHAPTER MORE THAN 6: ATTACKany other plant OF molecule,THE OXALATES polyphenols have become associated with the term “superfoods.” They are often dubbed “antioxidants,” and we are told to consume as much of them as possible. It seemsIN THE that FREQUENTLYPREVIOUS every day, two another chapters, ASKEDcompany we talked comes QUESTIONS about out plant with defense a supposedly chemicals magicalthat can supplement, have damaging juice, effectsor powder in ourwith bodiesbold claimsbecause of they’redecreased not inflammationcompatible with and ourlongevity human as operating it touts itssystem. robust In polyphenol this chapter, content. we’re Let’sgoing WHEN I STARTED writing this book, I knew that I would never be able to talkto talkabout about what apolyphenols molecule that actually is produced are and inwhy small we’ve quantities been told as they a waste are address every single possible question that arose from it—that’s what my 2223-2228.Textgoodproduct excerpted for ofus. human Then from metabolismwe’ll thesediscuss but chapters, why occurs I’m in going veryfollowed largeto take amounts bythe text,radically in some tables, next books are for. In an effort to be as comprehensive as possible, 38. Lawrence,contraryplants, andviewpointJ. R.,can Peter,cause that serious theirR., Baxter,purported pain, kidney G. benefits J., stones, Robson, are andnothing other J., moreGraham, issues than when the A. it B., & however,and I am comments including this copied section from to address the manyweb commonlypage listed asked stuffaccumulates of imagination, in our body.
    [Show full text]
  • The Effect of Biological Treatment on Behavior and Communication of Children on the Autistic Spectrum
    The Effect of Biological Treatment on Behavior and Communication of Children on the Autistic Spectrum Thesis submitted for the degree of Doctor of Philosophy At the University of Natural Medicine, Santa Fe by Anva Ohn-Bar, M.S. OTR Amirim, Israel May, 2006 Acknowledgements I would like to thank all the people who assisted me in this difficult and complicated project. First and foremost I thank and I appreciate the 9 families of the Autistic and PDD children, who cooperated, received my counseling and took my advice. I know how difficult it was. The beneficial changes most of them brought to their children's lives had an important influence on me. It was frustrating not to get cooperation from the rest of the families, and only because of the ones who did implement the program, I had the energy to continue and believe in what I do. I thank Annette Kahan, PhD. for all her assistance, wise feedback and expert comments. I thank Dr. Adiel Tel-Oren, for his support and useful comments and ideas. I also thank my family, who had to put up with a very busy and tired mother all this time…and especially my son Eshed, who helped me so much with the computer, the charts and all the technical part of writing… And last but not least, my husband Ohn, who supported me throughout the process. Without his love and patience I would have never completed this project. i Table of Contents Page Abstract iv Chapter 1: Introduction – why did I choose this subject? 1 The problem and the purpose of the study Chapter 2: Literature Review 5 Introduction - The spectrum of Neuro-behavioral disorders 5 A.
    [Show full text]